# Pharmacokinetics of rFVIIIFc at Two Vial Strengths

> **NCT02083965** · PHASE1 · COMPLETED · sponsor: **Bioverativ Therapeutics Inc.** · enrollment: 19 (actual)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **BIOLOGICAL:** rFVIIIFc

## Key facts

- **NCT ID:** NCT02083965
- **Lead sponsor:** Bioverativ Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-10
- **Final completion:** 2015-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083965, "Pharmacokinetics of rFVIIIFc at Two Vial Strengths". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02083965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*